The role of sulfamide derivatives in medicinal chemistry: A patent review (2006-2008)

Expert Opinion on Therapeutic Patents

Volumn 19, Issue 10, 2009, Pages 1449-1453

  Reitz, Allen B ^a   Smith, Garry R ^b   Parker, Michael H ^c  

^a Pennsylvania Biotechnology Center   (United States)

^b Fox Chase Chemical Diversity Center Inc   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Acylsulfamides; Anticonvulsant; Bioisostere; Carbonic anhydrase; Chemokine receptor; Endothelin receptor antagonists; Monoamine uptake inhibitors; Potassium channels; PPAR agonists; Sulfamide; Sulfonamide; Therapeutic

Indexed keywords

3 (BENZOTHIOPHENYL)METHYLSULFAMIDE; ACYLSULFAMIDE; ANTICONVULSIVE AGENT; ANTIVIRUS AGENT; CHEMOKINE RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; FENOFIBRATE; SULFAMIDE DERIVATIVE; SULFONAMIDE; UNCLASSIFIED DRUG; WO 2006023861; WO 2007137164; WO 2007137167;

ANTICONVULSANT ACTIVITY; ANTIVIRAL ACTIVITY; CYCLIZATION; DRUG STRUCTURE; HEPATITIS C VIRUS; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID METABOLISM; NONHUMAN; PATENT; PULMONARY HYPERTENSION; REVIEW; SEIZURE;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; PATENTS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TIME FACTORS;

EID: 70349763289     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770903185920     Document Type: Review

References (18)

1. Winum JY, Scozzafava A, Montero JL, Supuran CT. Therapeutic potential of sulfamides as enzyme inhibitors. Med Res Rev 2006;26:767-792 • General and useful overview of the role of sulfamides in medicinal chemistry. (Pubitemid 44735553)
2. Winum JY, Scozzafava A, Montero JL, Supuran CT. The sulfamide motif in the design of enzyme inhibitors. Expert Opin Ther Patents 2006;16:27-47 (Pubitemid 43056401)
3. Crystalgenomics, Inc. Sulfamide derivatives and pharmaceutical compositions for upregulation of lipid metabolism comprising same. WO2006006832; 2006
4. Actelion Pharmaceutical, Ltd. Novel sulfamides. WO2006051502; 2006
5. Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008;327:736-745
6. BASF Aktiengelellschaft, method for production of 1-alkyl-3- phenyluracils. WO 2006125746; 2006
7. Bristol-Myers Squibb Company. Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors. US 2007270405; 2007
8. Bristol-Myers Squibb Company. Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors. US 2007275930; 2007
9. Sanofi-Aventis Deutschland GMBH. Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them. WO 2006063722; 2006
10. AstraZeneca UK Limited. Pyrimidine sulfonamide derivatives as chemokine receptor modulators. WO 2006024823; 2006
11. Johnson & Johnson. Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents. US 2006276528-A1; 2006
12. Janssen Pharmaceutica, N.V. Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents. WO 2006023861-A1; 2006
13. Janssen Pharmaceutica, N.V. Co-therapy for the treatment of epilepsy Zand related disorders. WO 2007137164-A2; 2007
14. Janssen Pharmaceutica, N.V. Co-therapy for the treatment of epilepsy and related disorders. WO 2007137167-A2; 2007
15. Maryanoff BE, McComsey DF, Costanzo MJ, et al. Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform. J Med Chem 2005;48:1941-1947
16. Wyeth. Substituted benzothiadiainedioxide derivatives and methods of their use. WO 200873958-A2; 2008
17. Sanofi-Aventis Deutschland GMBH. Substituted benzoylguandines method for production and use thereof as medicament or diagnostic and medicament comprising the same. WO 2006050830-A1; 2006
18. Bristol-Myers Squibb Company. Indole inhibitors of 15-lipogenase. US 20060063822-A1; 2006